crinetics.png
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
October 26, 2020 07:02 ET | Crinetics Pharmaceuticals, Inc.
ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy   Paltusotine was observed to be well tolerated among...
crinetics.png
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
September 21, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Participate in September Investor Conferences
September 03, 2020 17:56 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), today announced that management will participate in the following conferences in the month of September and...
Reports and Data.jpeg-01
Immunoassay Analyzers Market To Reach USD 26.40 Billion By 2027 | Reports and Data
August 27, 2020 17:00 ET | Reports and Data
New York, Aug. 27, 2020 (GLOBE NEWSWIRE) -- The Global Immunoassay Analyzers market is forecast to reach USD 26.40 Billion by 2027, according to a new report by Reports and Data. Immunoassay...
crinetics.png
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 07, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study...
crinetics.png
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 17, 2020 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 17, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 15, 2020 00:21 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 15, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
April 14, 2020 16:05 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 14, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
January 08, 2020 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
crinetics.png
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference
September 25, 2019 07:30 ET | Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 25, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...